Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Core Viewpoint - Microbot Medical Inc. has announced a registered direct offering and a concurrent private placement to raise approximately $13 million for the development of its LIBERTY Robotic System and other corporate purposes [1][3]. Group 1: Offering Details - The company will sell 6,103,289 shares of common stock at a price of $2.13 per share in a registered direct offering [1]. - In addition, the company will issue unregistered short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock, also at an exercise price of $2.13 per share [1]. - The closing of these offerings is expected to occur on or about February 11, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offerings will be used for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System, as well as for expanding applications from the existing IP portfolio and for working capital [3]. Group 3: Regulatory Information - The common stock is being offered under a "shelf" registration statement previously filed with the SEC, which was declared effective on December 4, 2023 [4]. - The short-term series I preferred investment options are being issued in a private placement and have not been registered under the Securities Act [5]. Group 4: Company Overview - Microbot Medical Inc. is a clinical stage medical technology company focused on improving patient care through innovative solutions, including the development of the world's first single-use, fully disposable endovascular robotic system [7].